US equities
|
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
META
$721.31
▼-2.38%
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
META
$721.31
▼-2.38%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Vanguard U.S. Momentum Factor ETF
(NY:
VFMO
)
228.78
-2.51 (-1.09%)
Official Closing Price
Updated: 8:00 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vanguard U.S. Momentum Factor ETF
< Previous
1
2
3
Next >
Caleres Draws ‘Less Risk’ Rating From Telsey, Retail Chatter Surges 700%
↗
September 05, 2025
Via
Stocktwits
Summit Therapeutics Gets A $40 Price Target As Guggenheim Says It Likes Stock At $24, Like It Did At $3
↗
September 04, 2025
The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday.
Via
Stocktwits
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More
↗
September 04, 2025
While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7.
Via
Stocktwits
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update
↗
September 02, 2025
The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.
Via
Stocktwits
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’
↗
August 19, 2025
Via
Stocktwits
Lyft Has A ‘Steady Path Forward’ According To UBS: Retail Thinks Stock Is Undervalued
↗
August 15, 2025
Via
Stocktwits
Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming
↗
August 05, 2025
Via
Stocktwits
Vertex Stock Sinks 12% As Pipeline Setbacks Trigger Wall Street Skepticism: But Retail Sees Opportunity
↗
August 05, 2025
Via
Stocktwits
Oscar Health Now Expects Loss From Operations Of $200M To $300M In 2025: Here’s What Retail Thinks About The Stock Price
↗
July 22, 2025
Via
Stocktwits
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
↗
August 13, 2025
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.
Via
Stocktwits
Hims & Hers Announces Plans To Expand Into Canada As Novo Nordisk’s Weight Loss Drug Patent Expires
↗
July 09, 2025
The telehealth company stated that its entry to Canada will come as generic semaglutide hits the market for the first time.
Via
Stocktwits
Topics
Intellectual Property
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity
↗
July 09, 2025
Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity.
Via
Stocktwits
Topics
Government
KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated
↗
July 07, 2025
Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous...
Via
Stocktwits
AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report
↗
July 03, 2025
While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, Bloomberg reported, while noting that...
Via
Stocktwits
5 Surprising Vanguard ETFs That Could Beat the Market
↗
February 20, 2025
Not all Vanguard ETFs are the index funds you're probably familiar with.
Via
The Motley Fool
Topics
ETFs
After Beating the S&P 500 in 2024, This Vanguard Growth ETF Is Already Up Over 6% in 2025
↗
January 28, 2025
Via
The Motley Fool
Topics
ETFs
Stocks
Don't Miss This Actively Managed Vanguard ETF That Could Supercharge Your Returns
↗
October 26, 2024
This Vanguard fund could help diversify your ETF portfolio.
Via
The Motley Fool
Topics
ETFs
Vanguard ETFs: An Overview
↗
April 27, 2024
This ETF family is renowned for high capital returns, low expenses, and upholding management practices that prioritize shareholder interests.
Via
The Motley Fool
Topics
ETFs
This Is the Perfect Vanguard ETF for Investors With a Fear of Missing Out on the Market's Biggest Winners
↗
April 06, 2024
Don't fear: There's an ETF that will ensure you don't miss out on any high-flying stocks.
Via
The Motley Fool
Topics
ETFs
Like the "Magnificent Seven" Stocks? You'll Love This Vanguard ETF.
↗
March 25, 2024
This Vanguard ETF is a great way to invest in momentum stocks.
Via
The Motley Fool
Topics
ETFs
ETF Battles: Looking For The Best Momentum Stock ETF? It's MTUM vs. MTMM vs. JMOM vs. VFMO!
↗
January 23, 2022
In this episode of ETF Battles, Ron DeLegge @ETFguide referees an audience requested quadruple-header duel between 4 momentum focused stock ETFs.
Via
Talk Markets
< Previous
1
2
3
Next >
